Vicadrostat is an investigational medication being studied for treating chronic kidney disease. It is being tested to see how it affects kidney function when used in combination with another medication.

Empagliflozin is a medication that helps lower blood sugar levels and has been shown to have beneficial effects on kidney function. It belongs to a class of medications called SGLT2 inhibitors, which work by helping the kidneys remove excess sugar from the blood through urination. This medication is already approved for use in patients with type 2 diabetes and certain heart and kidney conditions.

The trial is studying whether it’s better to start both medications at the same time or to start them one after another (staggered approach) in people with chronic kidney disease who are at risk of their condition getting worse.

Chronic Kidney Disease – A long-term condition where the kidneys gradually lose their ability to filter waste and excess fluid from the blood. The disease typically develops over many years as the tiny filtering units in the kidneys become damaged. This condition often progresses silently in its early stages, with symptoms becoming more noticeable as kidney function declines. It can affect various bodily functions, including blood pressure regulation and red blood cell production. The disease may cause fluid retention, changes in urination patterns, and alterations in blood chemistry.